ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

ZURAMPIC
Gout
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

ZURAMPIC Rx

Generic Name and Formulations:
Lesinurad 200mg; tabs.

Company:
Ironwood Pharmaceuticals

Therapeutic Use:

Indications for ZURAMPIC:

In combination with a xanthine oxidase inhibitor, to treat hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.

Limitations Of use:

Not for treatment of asymptomatic hyperuricemia. Not for use as monotherapy.

Adult:

Take in the AM with food and water. 200mg once daily with a xanthine oxidase inhibitor (including allopurinol or febuxostat). Max 200mg daily. Patients on daily allopurinol dose <300mg (or <200mg with eCLCr <60mL/min): not recommended.

Children:

<18yrs: not established.

Contraindications:

Severe renal impairment (eCLCr <30mL/min), ESRD, kidney transplant recipients, or dialysis patients. Tumor lysis syndrome or Lesch-Nyhan syndrome.

Warnings/Precautions:

Risk of acute renal failure when used without a xanthine oxidase inhibitor. Assess renal function prior to initiation and periodically thereafter. Renal impairment (eCLCr <45mL/min): do not initiate. If eCLCr <60mL/min or with serum creatinine (SCr) elevations 1.5–2X pre-treatment value: monitor more frequently; if SCr >2X pre-treatment value: interrupt treatment. Discontinue therapy if eCLCr is persistently <45mL/min. Maintain adequate hydration (2 liters of liquid per day). Give gout flare prophylaxis. Severe hepatic impairment: not recommended. Females should use additional non-hormonal methods of contraception. Pregnancy. Nursing mothers.

Interactions:

Caution with concomitant moderate CYP2C9 inhibitors (eg, fluconazole, amiodarone) and in CYP2C9 poor metabolizers. Antagonized by moderate CYP2C9 inducers (eg, rifampin, carbamazepine), aspirin >325mg/day (in combination with allopurinol). Antagonizes CYP3A substrates (eg, sildenafil, amlodipine). May affect sensitive CYP3A substrates (eg, HMG-CoA reductase inhibitors); monitor. Concomitant epoxide hydrolase inhibitors (eg, valproic acid): not recommended. May reduce efficacy of hormonal contraceptives.

Pharmacological Class:

URAT1 inhibitor.

Adverse Reactions:

Headache, influenza, blood creatinine increase, GERD; gout flares, renal events, cardiovascular events.

Generic Availability:

NO

How Supplied:

Tabs—5, 30, 90

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs